Bruker Corporation has announced a global settlement with 10x Genomics, effectively ending all ongoing litigation between the two companies. The settlement includes global patent cross license agreements, leading to the dismissal of multiple lawsuits and administrative proceedings in various countries, including the United States and Germany. This resolution allows both companies to focus on their contributions to the scientific community without the distraction of legal disputes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.